Clinical Trial

Prospective Electronic Polygenic Risk Study - Second Phase

Study acronym: PEPRS2
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2022 (before its estimated January 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study will investigate the role of polygenic risk scores (PRS) in preventive health.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-12-13.
Trial Details
NCT Number NCT05175651
Lead Sponsor Scripps Translational Science Institute
Collaborators: Illumina, Inc., Optum, Inc., Quest Diagnostics-Nichols Insitute
Conditions Coronary Artery Disease, Glaucoma
Enrollment 10,000 participants
Start Date 2023-06
Primary Completion 2025-01-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2022-11-07